Diabetic retinopathy progression 6 months post-cataract surgery with intravitreous bevacizumab vs triamcinolone: A secondary analysis of the DiMECAT trial.
Main finding: Intravitreal bevacizumab and triamcinolone acetonide had decreased progression of diabetic retinopathy compared to previous studies where no adjunctive treatment was administered.
Purpose: To evaluate the progression of diabetic retinopathy in patients treated with intravitreal bevacizumab or triamcinolone at the time cataract surgery
Study type: Randomized controlled trial
Condition: Cataract surgery in diabetics
Participants: Diabetic patients with fovea-involving diabetic macular oedema plus visually significant cataract
n=61
Intervention:
Group 1: Intravitreal bevacizumab 1.25mg
Group 2: Intravitreal triamcinolone 4mg
Intravitreal bevacizumab and triamcinolone acetonide had decreased progression of diabetic retinopathy compared to previous studies where no adjunctive treatment was administered.
Share This Article :
Please provide feedback on content published. Thank you.
Source Archive